References:
1.Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers 2021; 7 (1): 33.
2.Petersen RC, Wiste HJ, Weigand SD, et al. NIA-AA Alzheimer’s disease framework: clinical characterization of stages. Ann Neurol 2021; 89 (6): 1145–1156.
3.Therriault J, Zimmer ER, Benedet AL, et al. Staging of Alzheimer’s disease: past, present, and future perspectives. Trends Mol Med 2022; 28 (9): 726–741.
4.Jack CR Jr, Bennett DA, Blennow K, et al; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14 (4): 535–562.
5.Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer’s disease. Alzheimers Dement 2023; 19 (4): 1227–1233.
6.McDade E, Bednar MM, Brashear HR, et al. The pathway to secondary prevention of Alzheimer’s disease. Alzheimers Dement (NY) 2020; 6 (1): e12069.
7.Dubois B, Padovani A, Scheltens P, et al. Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alzheimers Dis 2016; 49 (3): 617–631.
8.Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement 2022; 18 (12): 2669–2686.
